Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia

Pfizer

Status and phase

Completed

Phase 3

Conditions

Hyperlipidemia

Hypercholesterolemia, Familial

Treatments

Drug: atorvastatin

Drug: torcetrapib/atorvastatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00134485

A5091026

Details and patient eligibility

About

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial hypercholesterolemia

Full description

For additional information please call: 1-800-718-1021

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of Heterozygous Familial Hypercholesterolemia
At least 18 years of age

Exclusion criteria

Women who are pregnant or lactating, or planning to become pregnant.
Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study